{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:30:25Z","timestamp":1777926625656,"version":"3.51.4"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"vor","delay-in-days":270,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072020"],"award-info":[{"award-number":["82072020"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["20Z11900100"],"award-info":[{"award-number":["20Z11900100"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Key Clinical Specialty Project","award":["20220621102920000689"],"award-info":[{"award-number":["20220621102920000689"]}]},{"name":"Academician Expert Workstation","award":["19R1002275468"],"award-info":[{"award-number":["19R1002275468"]}]},{"name":"Academician Expert Workstation","award":["20R9004076411"],"award-info":[{"award-number":["20R9004076411"]}]},{"name":"Academician Expert Workstation","award":["21R4007547098"],"award-info":[{"award-number":["21R4007547098"]}]},{"name":"Shanghai Yuansong Biotechnology Limited Company"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The development of new therapies for malignant gliomas has been stagnant for decades. Through the promising outcomes in clinical trials of oncolytic virotherapy, there is now a glimmer of hope in addressing this situation. To further enhance the antitumor immune response of oncolytic viruses, we have equipped a modified oncolytic adenovirus (oAds) with a recombinant interferon-like gene (YSCH-01) and conducted a comprehensive evaluation of the safety and efficacy of this modification compared to existing treatments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>To assess the safety of YSCH-01, we administered the oAds intracranially to Syrian hamsters, which are susceptible to adenovirus. The efficacy of YSCH-01 in targeting glioma was evaluated through in vitro and in vivo experiments utilizing various human glioma cell lines. Furthermore, we employed a patient-derived xenograft model of recurrent glioblastoma to test the effectiveness of YSCH-01 against temozolomide.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>By modifying the E1A and adding survivin promoter, the oAds have demonstrated remarkable safety and an impressive ability to selectively target tumor cells. In animal models, YSCH-01 exhibited potent therapeutic efficacy, particularly in terms of its distant effects. Additionally, YSCH-01 remains effective in inhibiting the recurrent GBM patient-derived xenograft model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our initial findings confirm that a double-modified oncolytic adenovirus armed with a recombinant interferon-like gene is both safe and effective in the treatment of malignant glioma. Furthermore, when utilized in combination with a targeted therapy gene strategy, these oAds exhibit a more profound effect in tumor therapy and an enhanced ability to inhibit tumor growth at remote sites.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/noajnl\/vdad117","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T21:17:40Z","timestamp":1695849460000},"source":"Crossref","is-referenced-by-count":4,"title":["Double-modified oncolytic adenovirus armed with a recombinant interferon-like gene enhanced abscopal effects against malignant glioma"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1015-126X","authenticated-orcid":false,"given":"Shan","family":"Jiang","sequence":"first","affiliation":[{"name":"National Center for Neurological Disorders , Shanghai , China"},{"name":"Department of Neurosurgery, Huashan Hospital, Fudan University , Shanghai , China"},{"name":"Neurosurgical Institute, Fudan University , Shanghai , China"},{"name":"Shanghai Clinical Medical Center of Neurosurgery , Shanghai , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Hui","family":"Chai","sequence":"additional","affiliation":[{"name":"National Center for Neurological Disorders , Shanghai , China"},{"name":"Department of Neurosurgery, Huashan Hospital, Fudan University , Shanghai , China"},{"name":"Neurosurgical Institute, Fudan University , Shanghai , China"},{"name":"Shanghai Clinical Medical Center of Neurosurgery , Shanghai , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian-Long","family":"Fang","sequence":"additional","affiliation":[{"name":"Academician Expert Workstation of Fengxian District, Shanghai Yuansong Biotechnology Limited Company , Shanghai , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hou-Shi","family":"Xu","sequence":"additional","affiliation":[{"name":"National Center for Neurological Disorders , Shanghai , China"},{"name":"Department of Neurosurgery, Huashan Hospital, Fudan University , Shanghai , China"},{"name":"Neurosurgical Institute, Fudan University , Shanghai , China"},{"name":"Shanghai Clinical Medical Center of Neurosurgery , Shanghai , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian-Wen","family":"Li","sequence":"additional","affiliation":[{"name":"National Center for Neurological Disorders , Shanghai , China"},{"name":"Department of Neurosurgery, Huashan Hospital, Fudan University , Shanghai , China"},{"name":"Neurosurgical Institute, Fudan University , Shanghai , China"},{"name":"Shanghai Clinical Medical Center of Neurosurgery , Shanghai , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi-Sheng","family":"Tang","sequence":"additional","affiliation":[{"name":"National Center for Neurological Disorders , Shanghai , China"},{"name":"Department of Neurosurgery, Huashan Hospital, Fudan University , Shanghai , China"},{"name":"Neurosurgical Institute, Fudan University , Shanghai , China"},{"name":"Shanghai Clinical Medical Center of Neurosurgery , Shanghai , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Fa","family":"Gu","sequence":"additional","affiliation":[{"name":"Academician Expert Workstation of Fengxian District, Shanghai Yuansong Biotechnology Limited Company , Shanghai , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang-Jian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Academician Expert Workstation of Fengxian District, Shanghai Yuansong Biotechnology Limited Company , Shanghai , China"},{"name":"Institute of Smart Biomedical Materials, School of Materials Science and Engineering, Zhejiang Sci-Tech University , Hangzhou , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Yuan","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences , Shanghai , China"},{"name":"Xinyuan Institute of Medicine and Biotechnology, Zhejiang Sci-Tech University , Hangzhou , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Feng","family":"Shi","sequence":"additional","affiliation":[{"name":"National Center for Neurological Disorders , Shanghai , China"},{"name":"Department of Neurosurgery, Huashan Hospital, Fudan University , Shanghai , China"},{"name":"Neurosurgical Institute, Fudan University , Shanghai , China"},{"name":"Shanghai Clinical Medical Center of Neurosurgery , Shanghai , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-Ping","family":"Cao","sequence":"additional","affiliation":[{"name":"Academician Expert Workstation of Fengxian District, Shanghai Yuansong Biotechnology Limited Company , Shanghai , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zan-Yi","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The First Affiliated Hospital of Fujian Medical University , Fuzhou, Fujian , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang-Fu","family":"Zhou","sequence":"additional","affiliation":[{"name":"National Center for Neurological Disorders , Shanghai , China"},{"name":"Department of Neurosurgery, Huashan Hospital, Fudan University , Shanghai , China"},{"name":"Neurosurgical Institute, Fudan University , Shanghai , China"},{"name":"Shanghai Clinical Medical Center of Neurosurgery , Shanghai , China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"issue":"3","key":"2023101314031025800_CIT0001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"issue":"9","key":"2023101314031025800_CIT0002","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/s43018-021-00250-4","article-title":"Moving pan-cancer studies from basic research toward the clinic","volume":"2","author":"Chen","year":"2021","journal-title":"Nat Cancer"},{"issue":"4","key":"2023101314031025800_CIT0003","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamaoncol.2019.6143","article-title":"Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma","volume":"6","author":"Molinaro","year":"2020","journal-title":"JAMA Oncol"},{"issue":"10","key":"2023101314031025800_CIT0004","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"issue":"23","key":"2023101314031025800_CIT0005","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA."},{"issue":"4","key":"2023101314031025800_CIT0006","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/1078-0432.CCR-21-2750","article-title":"Glioblastoma clinical trials: Current landscape and opportunities for improvement","volume":"28","author":"Bagley","year":"2022","journal-title":"Clin Cancer Res."},{"issue":"26","key":"2023101314031025800_CIT0007","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1056\/NEJMoa2202028","article-title":"Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma","volume":"386","author":"G\u00e1llego P\u00e9rez-Larraya","year":"2022","journal-title":"N Engl J Med."},{"issue":"8","key":"2023101314031025800_CIT0008","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S1470-2045(21)00245-X","article-title":"Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: A first-in-human, phase 1, dose-escalation trial","volume":"22","author":"Fares","year":"2021","journal-title":"Lancet Oncol."},{"issue":"2","key":"2023101314031025800_CIT0009","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N Engl J Med."},{"issue":"8","key":"2023101314031025800_CIT0010","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: A phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat Med."},{"issue":"3","key":"2023101314031025800_CIT0011","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.cell.2019.01.008","article-title":"A paradigm shift in cancer immunotherapy: From enhancement to normalization","volume":"176","author":"Sanmamed","year":"2019","journal-title":"Cell."},{"issue":"7","key":"2023101314031025800_CIT0012","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","article-title":"Turning cold into hot: Firing up the tumor microenvironment","volume":"6","author":"Duan","year":"2020","journal-title":"Trends Cancer"},{"issue":"8","key":"2023101314031025800_CIT0013","doi-asserted-by":"crossref","first-page":"e1442169","DOI":"10.1080\/2162402X.2018.1442169","article-title":"Heating it up: Oncolytic viruses make tumors \u201chot\u201d and suitable for checkpoint blockade immunotherapies","volume":"7","author":"Gujar","year":"2018","journal-title":"Oncoimmunology"},{"issue":"1","key":"2023101314031025800_CIT0014","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1038\/s41467-022-31262-y","article-title":"A phase I\/II study of triple-mutated oncolytic herpes virus G47 in patients with progressive glioblastoma","volume":"13","author":"Todo","year":"2022","journal-title":"Nat Commun."},{"issue":"8","key":"2023101314031025800_CIT0015","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1158\/1078-0432.CCR-16-1386","article-title":"A potent in vivo antitumor efficacy of novel recombinant type I interferon","volume":"23","author":"Zhang","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2023101314031025800_CIT0016","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1073\/pnas.95.5.2509","article-title":"A simplified system for generating recombinant adenoviruses","volume":"95","author":"He","year":"1998","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"2023101314031025800_CIT0017","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"Fueyo","year":"2000","journal-title":"Oncogene."},{"issue":"4","key":"2023101314031025800_CIT0018","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0168-1702(89)90026-9","article-title":"Restricted replication of human adenovirus type 5 in mouse cell lines","volume":"14","author":"Blair","year":"1989","journal-title":"Virus Res."},{"issue":"8","key":"2023101314031025800_CIT0019","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/cgt.2009.6","article-title":"INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: Comparison of biodistribution studies","volume":"16","author":"Ying","year":"2009","journal-title":"Cancer Gene Ther."},{"issue":"2","key":"2023101314031025800_CIT0020","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/imm.12116","article-title":"The adaptive immune response does not influence hantavirus disease or persistence in the Syrian hamster","volume":"140","author":"Prescott","year":"2013","journal-title":"Immunology."},{"key":"2023101314031025800_CIT0021","doi-asserted-by":"crossref","first-page":"S271","DOI":"10.1093\/infdis\/jiv203","article-title":"Natural immunity to ebola virus in the syrian hamster requires antibody responses","volume":"212","author":"Prescott","year":"2015","journal-title":"J Infect Dis."},{"issue":"3","key":"2023101314031025800_CIT0022","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-05-3497","article-title":"Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors","volume":"66","author":"Thomas","year":"2006","journal-title":"Cancer Res."},{"issue":"1","key":"2023101314031025800_CIT0023","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ymthe.2022.08.021","article-title":"CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol Ther"},{"issue":"1","key":"2023101314031025800_CIT0024","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41467-020-15229-5","article-title":"An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun."},{"key":"2023101314031025800_CIT0025","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.omto.2020.04.006","article-title":"In situ therapeutic cancer vaccination with an oncolytic virus expressing membrane-tethered IL-2","volume":"17","author":"Liu","year":"2020","journal-title":"Mol Ther Oncolytics."},{"issue":"12","key":"2023101314031025800_CIT0026","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1016\/j.ymthe.2022.06.010","article-title":"An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen-presenting cells in situ","volume":"30","author":"Ye","year":"2022","journal-title":"Mol Ther"},{"issue":"13","key":"2023101314031025800_CIT0027","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1158\/0008-5472.CAN-21-0035","article-title":"An oncolytic virus expressing IL15\/IL15R\u03b1 combined with off-the-shelf EGFR-CAR NK cells targets glioblastoma","volume":"81","author":"Ma","year":"2021","journal-title":"Cancer Res."},{"issue":"11","key":"2023101314031025800_CIT0028","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/s43018-022-00448-0","article-title":"Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity","volume":"3","author":"Tian","year":"2022","journal-title":"Nat Cancer"},{"issue":"1","key":"2023101314031025800_CIT0029","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.intimp.2015.07.005","article-title":"Enhanced growth suppression of TERT-positive tumor cells by oncolytic adenovirus armed with CCL20 and CD40L","volume":"28","author":"Liu","year":"2015","journal-title":"Int Immunopharmacol."}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdad117\/51790993\/vdad117.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/5\/1\/vdad117\/52071304\/vdad117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/5\/1\/vdad117\/52071304\/vdad117.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T15:05:15Z","timestamp":1697209515000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdad117\/7285592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdad117","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2023,1,1]]},"article-number":"vdad117"}}